Company Profile
Hanmi has been a leading company in manufacturing Cephalosporin API for over 20 years. Hanmi was granted CoS for its Cefotaxime and Ceftriaxone in 1998. Recently, Hanmi was also granted CoS for Cefixime and foresees to receive CoS for Ceftazidime shortly. For ICE development, Hanmi's own patented Amlodipine new salt is under phase III and Sibutramine new salt is under pre-clinical stage. Another strength of Hanmi is its DDS technology. Hanmi launched Ibuprofen soft cap and Silymarin soft cap which improves bioavailability by using its microemulsion technology. Nifedipine CR tablet and Felodipine ER tablet are under BE study now.
